Physician profile
Bernice Gonzalez
NPI 1184622904
$7,040.55
in general payments reported to CMS, 2019-2025
52 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $561 · 2021: $1,333 · 2022: $1,006 · 2023: $2,572 · 2024: $491 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,205 · Food and Beverage: $1,184 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,205.00 |
| Food and Beverage | $1,184.07 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $2,466.85 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $518.61 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $408.92 | 2020-2022 | |
| Abbvie INC. | $306.11 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $248.65 | 2022 | |
| Amarin Pharma, INC. | $224.32 | 2019-2022 | |
| Eisai INC. | $210.91 | 2019-2022 | |
| Ibsa Pharma INC. | $184.45 | 2019-2025 | Tirosint, Licart, Flector |
| Astellas Pharma US INC | $166.88 | 2025 | Veozah |
| Amgen INC. | $165.16 | 2020-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $161.40 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.96 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $134.00 | 2019-2021 | |
| Lilly USA, LLC | $131.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $124.98 | 2025 | Auvelity |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernice Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.